<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29200" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sodium Nitroprusside</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Holme</surname>
            <given-names>Matthew R.</given-names>
          </name>
          <aff>American University of the Caribbean School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharman</surname>
            <given-names>Tariq</given-names>
          </name>
          <aff>Southern Ohio Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Holme declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tariq Sharman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29200.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Sodium nitroprusside is a medication used in the management of acute hypertension. It is a potent vasodilator and is administered as an IV infusion with intensive monitoring in place. This activity reviews the major indications, action, contraindications, and toxicity of sodium nitroprusside. This activity will also highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring) pertinent for the interprofessional healthcare team members in the management of patients with acute hypertensive crises and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of sodium nitroprusside.</p></list-item><list-item><p>Describe the potential adverse effects of sodium nitroprusside.</p></list-item><list-item><p>Review the appropriate monitoring for the toxicity of sodium nitroprusside.</p></list-item><list-item><p>Outline some interprofessional team strategies for improving care coordination and communication to optimize the clinical use of sodium nitroprusside and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29200&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29200">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29200.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Sodium nitroprusside (SNP) is a potent vasodilator that first gained FDA approval for the treatment of severe hypertension in 1974. First discovered in 1849 by Playfair, its applications in human medicine can be traced back to the early 1920s, with the first safety and efficacy data published in 1955. After an initial delay in gaining&#x000a0;FDA approval due to&#x000a0;difficulty in the development of a chemically stable formulation,&#x000a0;SNP gained widespread use as a fast-acting antihypertensive agent and has been used clinically for hypertensive crises, heart failure, cardiac/vascular surgery, pediatric surgery, and a variety of other acute applications. While sodium nitroprusside's&#x000a0;potential adverse effects and toxicity have led to its replacement by newer agents in some practices, it&#x000a0;remains a&#x000a0;useful tool&#x000a0;in certain difficult clinical situations that require a potent, fast-acting, titratable vasodilator.<xref ref-type="bibr" rid="article-29200.r1">[1]</xref><xref ref-type="bibr" rid="article-29200.r2">[2]</xref></p>
        <p>Sodium nitroprusside has the following FDA-approved&#x000a0;indications:<xref ref-type="bibr" rid="article-29200.r3">[3]</xref><xref ref-type="bibr" rid="article-29200.r4">[4]</xref><xref ref-type="bibr" rid="article-29200.r5">[5]</xref><xref ref-type="bibr" rid="article-29200.r6">[6]</xref><xref ref-type="bibr" rid="article-29200.r7">[7]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Acute hypertensive crises</p>
          </list-item>
          <list-item>
            <p>Acute decompensated heart failure</p>
          </list-item>
          <list-item>
            <p>Induction of perioperative hypotension (to reduce blood loss)</p>
          </list-item>
        </list>
        <p>&#x000a0;Off-label uses for nitroprusside include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension in the setting of acute ischemic stroke <xref ref-type="bibr" rid="article-29200.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Afterload reduction in acute mitral regurgitation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Increase cardiac output in cardiogenic shock and high SVR &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acute preload reduction in select patients with valvular aortic stenosis&#x000a0;<xref ref-type="bibr" rid="article-29200.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>Emerging applications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prevention and treatment of the "no-reflow" phenomenon in the percutaneous coronary intervention&#x000a0;<xref ref-type="bibr" rid="article-29200.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Symptomatic treatment of schizophrenia&#x000a0;<xref ref-type="bibr" rid="article-29200.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29200.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Sodium nitroprusside is a water-soluble salt comprised of ferrous iron complexed with nitric oxide (NO) and five cyanide ions. Acting as a prodrug, SNP reacts with sulfhydryl groups on erythrocytes (as well as albumin and other proteins) to produce nitric oxide (NO). Upon binding to vascular smooth muscle, NO triggers intracellular cGMP-mediated activation of protein kinase G and subsequent inactivation of myosin light chains, resulting in relaxation of vascular smooth muscle. The result of this signaling cascade is peripheral vasodilation of both arteries and veins (with slightly more selectivity for veins).&#x000a0;</p>
        <p>From a hemodynamic perspective, the net result is a decrease in systemic vascular resistance (afterload), ventricular filling pressures, and systemic blood pressure with an increase in cardiac output.&#x000a0;Onset is rapid (within 2 minutes), and the duration of its hypotensive effect is roughly 10 minutes; these properties make nitroprusside useful in situations requiring an immediate reduction in preload or afterload. In contrast to nitroglycerin, nitroprusside causes a more balanced vasodilatory effect between arteries and veins.<xref ref-type="bibr" rid="article-29200.r12">[12]</xref><xref ref-type="bibr" rid="article-29200.r13">[13]</xref></p>
      </sec>
      <sec id="article-29200.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Nitroprusside is administered only as an IV infusion diluted in D5W (it is not suitable for direct injection).&#x000a0;It&#x000a0;requires protection from light at all times.<xref ref-type="bibr" rid="article-29200.r14">[14]</xref></p>
        <p>Typical infusion rates range from 0.5&#x000a0;to 4 mcg/kg/minute which are then titrated to desired effect.&#x000a0;Typical infusion concentrations for adults are 200 mcg/mL or 400 mcg/mL.&#x000a0;</p>
        <p>The maximum infusion rate is approximately 10 mcg/kg/minute, not to be sustained for more than 10 minutes at a time.&#x000a0;If sufficient blood pressure control has not been achieved at that point, alternative agents should be considered (e.g., clevidipine).</p>
        <p>The half-life elimination of sodium nitroprusside in circulation is roughly 2 minutes. Once metabolized into thiocyanate, half-life elimination occurs in approximately three&#x000a0;days; renal dysfunction can easily double or triple this figure.</p>
        <p>SNP is ultimately excreted from the body via urine as&#x000a0;thiocyanate.&#x000a0;</p>
      </sec>
      <sec id="article-29200.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cardiovascular</bold>:
<list list-type="bullet"><list-item><p>Bradycardia</p></list-item><list-item><p>Tachycardia</p></list-item><list-item><p>Flushing</p></list-item><list-item><p>Palpitations</p></list-item><list-item><p>Severe hypotension</p></list-item><list-item><p>Electrocardiographic changes</p></list-item><list-item><p>Substernal chest pain</p></list-item><list-item><p>Shortness of breath</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Central Nervous System</bold>:
<list list-type="bullet"><list-item><p>Headache</p></list-item><list-item><p>Dizziness</p></list-item><list-item><p>Increased intracranial pressure</p></list-item><list-item><p>Apprehension</p></list-item><list-item><p>Restlessness</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Dermatologic:</bold>&#x000a0;
<list list-type="bullet"><list-item><p>Diaphoresis</p></list-item><list-item><p>Skin rash</p></list-item><list-item><p>Local skin irritation with&#x000a0;erythematous streaking</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Endocrine/Metabolic</bold>:
<list list-type="bullet"><list-item><p>Hypothyroidism</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Gastrointestinal</bold>:
<list list-type="bullet"><list-item><p>Abdominal pain</p></list-item><list-item><p>Nausea</p></list-item><list-item><p>Vomiting/retching</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Hematologic/Oncologic</bold>:
<list list-type="bullet"><list-item><p>Decreased platelet aggregation</p></list-item><list-item><p>Methemoglobinemia</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Musculoskeletal</bold>:
<list list-type="bullet"><list-item><p>Muscle twitching&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29200.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Nitroprusside is Contraindicated in the Following Situations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of compensatory hypertension, such as that seen with arteriovenous malformations or aortic coarctation</p>
          </list-item>
          <list-item>
            <p>SNP should not be used for inducing controlled perioperative hypotension in patients with known inadequate cerebral perfusion</p>
          </list-item>
          <list-item>
            <p>Acute heart failure with low systemic vascular resistance (e.g., septic shock)</p>
          </list-item>
          <list-item>
            <p>Leber's hereditary optic atrophy*</p>
          </list-item>
          <list-item>
            <p>Tobacco amblyopia*</p>
          </list-item>
          <list-item>
            <p>Vitamin B12 deficiency (or associated disease states)</p>
          </list-item>
          <list-item>
            <p>SNP must not be used simultaneously with phosphodiesterase inhibitors such as sildenafil, tadalafil, or vardenafil (due to the synergistic cGMP-mediated mechanism of action)</p>
          </list-item>
          <list-item>
            <p>Known hypersensitivity to nitroprusside or any component of the formulation&#x000a0;</p>
          </list-item>
        </list>
        <p>*These patients are deficient in rhodanese<italic toggle="yes">. </italic>(rhodanese, also known as rhodanase,&#x000a0;thiosulfate cyanide transsulfurase,&#x000a0;thiosulfate sulfurtransferase,&#x000a0;and&#x000a0;thiosulfate thiotransferase,&#x000a0;is a mitochondrial enzyme&#x000a0;that detoxifies cyanide&#x000a0;by converting it to thiocyanate).<italic toggle="yes"/></p>
        <p>
<bold>Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Before use for controlled perioperative hypotension, correct any underlying hypovolemia and/or anemia (if possible)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Use extreme caution in the setting of acute myocardial infarction in consideration of SNP's potent hemodynamic effects&#x000a0;and potential for inducing coronary steal.</p>
          </list-item>
          <list-item>
            <p>In the setting of hepatic impairment, use extreme caution; monitor closely for cyanide toxicity.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In the setting of renal dysfunction, use the lowest possible dose and monitor closely for thiocyanate toxicity.</p>
          </list-item>
        </list>
        <p>
<bold>Additional Considerations</bold>
</p>
        <p>Pregnancy&#x000a0;Category C</p>
        <list list-type="bullet">
          <list-item>
            <p>Although there is only limited information regarding the use of SNP in pregnancy, animal studies demonstrate its ability to cross the placental barrier, causing a dose-dependent increase in fetal cyanide levels.&#x000a0;</p>
          </list-item>
        </list>
        <p>Breastfeeding Considerations</p>
        <list list-type="bullet">
          <list-item>
            <p>While it is unclear if SNP is present in breast milk, the potential for serious adverse reactions in the infant warrant either discontinuation of breastfeeding or discontinuation of SNP depending on the clinical scenario.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29200.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Intensive hemodynamic monitoring is critical when administering nitroprusside. As a result, SNP has classically been restricted to highly monitored settings such as the ICU or operating theater. Continuous blood pressure monitoring is required using an indwelling arterial line. With prolonged infusions or high infusion rates, close attention should also be paid to acid-base balance and mixed venous oxygen concentration, as unexplained acidemia and/or hypoxemia are often early signs of cyanide toxicity. However, It should be noted that these laboratory measures may not always provide reliable guidance. In most settings, serum cyanide concentrations are not of practical use&#x000a0;due to long turnaround times. Thiocyanate levels can be monitored in high-risk patients (those with renal dysfunction and/or infusions &#x0003e;3 days).<xref ref-type="bibr" rid="article-29200.r15">[15]</xref></p>
      </sec>
      <sec id="article-29200.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The toxicity of nitroprusside is related to its potent antihypertensive effects and the accumulation of toxic metabolites (cyanide, thiocyanate, and methemoglobin).<xref ref-type="bibr" rid="article-29200.r16">[16]</xref></p>
        <p><bold>1. Cyanide toxicity:&#x000a0;</bold>Nitroprusside combines with hemoglobin and is subsequently metabolized to 5 cyanide ions and cyanmethemoglobin. Cyanide then converts to thiocyanate via rhodanese-mediated donation of a sulfur group (from thiosulfate or cysteine); this final step can quickly become overwhelmed with large quantities of the drug.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients at high risk for cyanide toxicity include those with hepatic impairment, malnourishment, vitamin B12 deficiency states, patients on cardiopulmonary bypass, and those undergoing therapeutic hypothermia.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cyanide toxicity may manifest in the form of metabolic acidosis, hypoxemia, bradycardia, altered mental status (e.g., confusion), and/or convulsions.</p>
          </list-item>
          <list-item>
            <p>If cyanide toxicity is suspected, the administration should be stopped immediately, and antidotal therapy given, preferably using a combination of hydroxocobalamin (to bind intracellular cyanide) and sodium thiosulfate (to act as a sulfur donor).&#x000a0;</p>
          </list-item>
        </list>
        <p>One strategy that has helped combat cyanide toxicity in patients receiving high doses or prolonged infusions of nitroprusside involves the co-administration of sodium thiosulfate (a sulfur group donor) at a 10&#x000a0;to 1 ratio.<xref ref-type="bibr" rid="article-29200.r17">[17]</xref> It is important to note that thiocyanate toxicity may still occur with this approach.<xref ref-type="bibr" rid="article-29200.r18">[18]</xref></p>
        <p><bold>2. Hypotension</bold>: Profound hypotension may occur with resultant compromised perfusion to vital organs</p>
        <p><bold>3. Thiocyanate toxicity</bold>: Thiocyanate toxicity rarely occurs, most often in the setting of renal failure and/or prolonged infusions (&#x0003e;72 hours).<xref ref-type="bibr" rid="article-29200.r19">[19]</xref><xref ref-type="bibr" rid="article-29200.r20">[20]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The earliest signs of thiocyanate toxicity are frequently tinnitus, abdominal pain, weakness, and variable levels of altered mental status (agitation, disorientation), which can ultimately progress to lethargy, seizures, and coma if not recognized and treated.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Of note, serum thiocyanate levels are only useful if used for confirmation of suspected toxicity in symptomatic patients. Early signs (e.g., tinnitus) may be present at levels above 35 mcg/mL, while symptoms of serious toxicity are expected with serum levels &#x0003e;100 mcg/mL.<xref ref-type="bibr" rid="article-29200.r19">[19]</xref></p>
          </list-item>
        </list>
        <p><bold>4. Methemoglobinemia</bold>: Methemoglobinemia most often occurs in patients receiving infusions &#x0003e;10 mcg/kg/minute and presents with signs of impaired oxygen delivery despite normal PaO2 and cardiac output.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>First-line treatment with methylene blue should be given in symptomatic patients or those with methemoglobin levels exceeding 30% (10% in those with preexisting conditions limiting tolerance to hypoxemia).&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>5. Increased intracranial pressure: </bold>a&#x000a0;result of cerebral vasodilation.</p>
      </sec>
      <sec id="article-29200.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Nitroprusside is a fast-acting, easily titratable, highly effective antihypertensive agent that must be used with extreme care. While its use has declined in recent years as newer agents have become available, this drug still has a role in treating hypertensive emergencies and other disease processes that require an urgent reduction in arterial blood pressure.&#x000a0;&#x000a0;</p>
        <p>Interprofessional communication is critical to the safe use of nitroprusside as these patients require intensive monitoring of hemodynamic parameters.&#x000a0;All members of the interprofessional healthcare team must be familiar with the potential adverse effects and toxicity syndromes. Careful patient selection based on comorbidities and risk factors is required, and clinicians&#x000a0;(surgeons, anesthesiologists, intensivists) should engage in shared decision-making with their pharmacists to assess each patient's risk factors and determine an appropriate dosing protocol. In utilizing this team-oriented approach, sodium nitroprusside can be a safe and effective therapeutic option for managing acutely hypertensive patients. [Level 5]</p>
      </sec>
      <sec id="article-29200.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29200&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29200">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29200/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29200">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29200.s11">
        <title>References</title>
        <ref id="article-29200.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friederich</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Butterworth</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Sodium nitroprusside: twenty years and counting.</article-title>
            <source>Anesth Analg</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>152</fpage>
            <page-range>152-62</page-range>
            <pub-id pub-id-type="pmid">7598246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hottinger</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Beebe</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kozhimannil</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Prielipp</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Belani</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Sodium nitroprusside in 2014: A clinical concepts review.</article-title>
            <source>J Anaesthesiol Clin Pharmacol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>462</fpage>
            <page-range>462-71</page-range>
            <pub-id pub-id-type="pmid">25425768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>WRITING COMMITTEE MEMBERS</collab>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Geraci</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Riegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wilkoff</surname>
                <given-names>BL</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>128</volume>
            <issue>16</issue>
            <fpage>e240</fpage>
            <page-range>e240-327</page-range>
            <pub-id pub-id-type="pmid">23741058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varon</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of acute severe hypertension: current and newer agents.</article-title>
            <source>Drugs</source>
            <year>2008</year>
            <volume>68</volume>
            <issue>3</issue>
            <fpage>283</fpage>
            <page-range>283-97</page-range>
            <pub-id pub-id-type="pmid">18257607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Skubas</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sorajja</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JD</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
            </person-group>
            <article-title>2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Jun</month>
            <day>10</day>
            <volume>129</volume>
            <issue>23</issue>
            <fpage>2440</fpage>
            <page-range>2440-92</page-range>
            <pub-id pub-id-type="pmid">24589852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erstad</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Barletta</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Treatment of hypertension in the perioperative patient.</article-title>
            <source>Ann Pharmacother</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-79</page-range>
            <pub-id pub-id-type="pmid">10669188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jauch</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Saver</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Demaerschalk</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McMullan</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Rosenfield</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Summers</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Wintermark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yonas</surname>
                <given-names>H</given-names>
              </name>
              <collab>American Heart Association Stroke Council</collab>
              <collab>Council on Cardiovascular Nursing</collab>
              <collab>Council on Peripheral Vascular Disease</collab>
              <collab>Council on Clinical Cardiology</collab>
            </person-group>
            <article-title>Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.</article-title>
            <source>Stroke</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>870</fpage>
            <page-range>870-947</page-range>
            <pub-id pub-id-type="pmid">23370205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikram</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Crozier</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Shirlaw</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Hemodynamic effects of nitroprusside on valvular aortic stenosis.</article-title>
            <source>Am J Cardiol</source>
            <year>1992</year>
            <month>Feb</month>
            <day>01</day>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-6</page-range>
            <pub-id pub-id-type="pmid">1734649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasceri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pristipino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pelliccia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Granatelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Speciale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roncella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pironi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Capasso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richichi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction.</article-title>
            <source>Am J Cardiol</source>
            <year>2005</year>
            <month>Jun</month>
            <day>01</day>
            <volume>95</volume>
            <issue>11</issue>
            <fpage>1358</fpage>
            <page-range>1358-61</page-range>
            <pub-id pub-id-type="pmid">15904643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hallak</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Maia-de-Oliveira</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Abrao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Evora</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Zuardi</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Crippa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Belmonte-de-Abreu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Dursun</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>70</volume>
            <issue>7</issue>
            <fpage>668</fpage>
            <page-range>668-76</page-range>
            <pub-id pub-id-type="pmid">23699763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fok</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clapp</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chowienczyk</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Regulation of vascular tone and pulse wave velocity in human muscular conduit arteries: selective effects of nitric oxide donors to dilate muscular arteries relative to resistance vessels.</article-title>
            <source>Hypertension</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>1220</fpage>
            <page-range>1220-5</page-range>
            <pub-id pub-id-type="pmid">23045465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ivankovich</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Miletich</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Tinker</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Sodium nitroprusside: metabolism and general considerations.</article-title>
            <source>Int Anesthesiol Clin</source>
            <year>1978</year>
            <season>Summer</season>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>1</fpage>
            <page-range>1-29</page-range>
            <pub-id pub-id-type="pmid">357297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmer</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Lasseter</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Drug therapy. Sodium nitroprusside.</article-title>
            <source>N Engl J Med</source>
            <year>1975</year>
            <month>Feb</month>
            <day>06</day>
            <volume>292</volume>
            <issue>6</issue>
            <fpage>294</fpage>
            <page-range>294-7</page-range>
            <pub-id pub-id-type="pmid">1089194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tinker</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Michenfelder</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Sodium nitroprusside: pharmacology, toxicology and therapeutics.</article-title>
            <source>Anesthesiology</source>
            <year>1976</year>
            <month>Sep</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>340</fpage>
            <page-range>340-54</page-range>
            <pub-id pub-id-type="pmid">962181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johanning</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Zaske</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Tschida</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Hoey</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Vance-Bryan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A retrospective study of sodium nitroprusside use and assessment of the potential risk of cyanide poisoning.</article-title>
            <source>Pharmacotherapy</source>
            <year>1995</year>
            <season>Nov-Dec</season>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>773</fpage>
            <page-range>773-7</page-range>
            <pub-id pub-id-type="pmid">8602386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schulz</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Elder</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Vijayan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Medow</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Stability of Sodium Nitroprusside and Sodium Thiosulfate 1:10 Intravenous Admixture.</article-title>
            <source>Hosp Pharm</source>
            <year>2010</year>
            <month>Oct</month>
            <day>01</day>
            <volume>45</volume>
            <issue>10</issue>
            <fpage>779</fpage>
            <page-range>779-784</page-range>
            <pub-id pub-id-type="pmid">21625332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rindone</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sloane</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Cyanide toxicity from sodium nitroprusside: risks and management.</article-title>
            <source>Ann Pharmacother</source>
            <year>1992</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>515</fpage>
            <page-range>515-9</page-range>
            <pub-id pub-id-type="pmid">1533553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Baumgartner</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>MacLaren</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Kiser</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Thiocyanate Accumulation in Critically Ill Patients Receiving Nitroprusside Infusions.</article-title>
            <source>J Intensive Care Med</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>547</fpage>
            <page-range>547-553</page-range>
            <pub-id pub-id-type="pmid">27435907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29200.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vesey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>PV</given-names>
              </name>
            </person-group>
            <article-title>Blood cyanide and thiocyanate concentrations produced by long-term therapy with sodium nitroprusside.</article-title>
            <source>Br J Anaesth</source>
            <year>1985</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>148</fpage>
            <page-range>148-55</page-range>
            <pub-id pub-id-type="pmid">3970795</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
